Source: Annual Congress 2002 - Interstitial lung disorders: markers of disease activity and severity
Disease area: Interstitial lung diseases

Abstract

We have previously shown MIP-3β protein and mRNA upregulation in patients with sarcoidosis (S). Here, we have concentrated on identifying MIP-3β source in bronchoalveolar lavage fluid (BALF) and on analysis of possible association of MIP-3β BALF protein levels with sarcoidosis clinical course [as assessed by chest X-ray (CXR) stage, need for treatment, and also serum sIL-2R levels]. MIP-3β protein levels were measured by ELISA in BALF from 78 patients with S. Regarding approximate assessment of disease course, patients were divided into 2 groups: 1) requiring corticosteroid treatment and 2) with spontaneous remission. MIP-3β cell-associated protein was detected by immunocytochemistry. Serum for ELISA sIL-2R measurements was available in 61 of 78 patients. MIP-3β protein levels were significantly elevated in patients with CXR Stage II (SII, n=25) in comparison to patients with Stage I (SI, n=48) (mean ±] SEM, pg/ml; SI: 47.9 ±] 21.6; SII: 145.4 ±] 43.4; p=0.003). MIP-3β+ve cells were identified mostly as alveolar macrophages. MIP-3β protein levels were higher in patients requiring treatment (n=40, 118.6 ±] 36.0) than in patients with spontaneous remission (n=38, 39.6 ±] 13.0); the difference, however, did not attain significance. MIP-3β protein levels correlated with sIL-2R, p=0.03. Our findings implicate chemokine MIP-3β as an interesting candidate for novel marker for supplementary immunodiagnostics of sarcoidosis and possibly also for monitoring of its clinical course. Further studies, also on MIP-3β in serum, are however warranted to validate this speculation.
Grant support from MSM.15110002.

Rating:

Share or cite this content

Citations should be made in the following way:
A. Gibejova, F. Mrazek, D. Subrtova, J. Szotkowska, V. Kolek, R. M. du Bois, M. Petrek (Olomouc, Czech Republic; London, United Kingdom). Relationship between macrophage inflammatory protein-3β(MIP-3β) levels and clinical course of sarcoidosis. Eur Respir J 2002; 20: Suppl. 38, 1116

Member's Comments

No comment yet.

Related content which might interest you: BALF TNFα level in relation to inflammatory status and phenotype of sarcoidosis Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis Year: 2012 TNF-alpha, IL-8, IL-6 levels in serum of sarcoidosis patients with different clinical course Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013 Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 The importance of inflammatory markers in sarcoidosis Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases Year: 2008 Role of systemic inflammation mediated by IL-6 and TNF-alpha cytokines in chronic obstructive pulmonary disease and its progression: A three year follow up study Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Relation of inflammatory process with COPD phenotype Source: Annual Congress 2012 - Inflammatory mechanisms in COPD Year: 2012 Correlation of serum TNF-α, IL-4 and sIL-2R levels with radiologic and clinical manifestations in active pulmonary tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 339s Year: 2003 Systemic inflammatory response in relation to disease severity and nutritional depletion in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 31s Year: 2004 Time course of systemic inflammatory markers during acute exacerbation of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 555s Year: 2007 Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009 Expression of CD282+/CD284+ on blood granulocytes and its relationship to cytokine status in patients with stable chronic obstructive pulmonary disease Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations Year: 2021 Temporal profile and clinical utility of inflammatory markers in patients with acute exacerbation of COPD Source: Annual Congress 2008 - Structural remodelling in COPD Year: 2008 Correlation of a progression of fibrotic changes in idiopathic pulmonary fibrosis 1 year after a diagnosis with initial functional and immunologic parameters Source: Eur Respir J 2004; 24: Suppl. 48, 667s Year: 2004 Serum exosomes from IPF patients display a fibrotic miRNA profile that correlates to clinical measures of disease severity Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Relationship between asthma and systemic inflammation Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung Year: 2010 Clinical significance of different cytokines expression in lung tissue in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 313s Year: 2002 Association between adipokines, inflammatory markers and systemic manifestations in chronic obstructive pulmonary disease (COPD) patients Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016 Relationship between systemic IFNγ and IL5 levels and exacerbation frequency in COPD Source: Eur Respir J 2001; 18: Suppl. 33, 153s Year: 2001 Relationship of systemic inflammation and autoimmunity to clinically relevant outcomes in COPD Source: Annual Congress 2011 - COPD mechanisms Year: 2011 The level of anti-inflammatory cytokine IL-10 in patients with chronic obstructive pulmonary disease of varying severity Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013